J. Carl Barrett

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Supplementary Figure S4 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

  2025-11-25

• Figure 3 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification

  2025-11-25

• Supplementary Figure S2 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

  2025-11-25

• Supplementary Figure S1 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

  2025-11-25

• Supplementary Table S1 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

  2025-11-25

• Supplementary Table S2 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

  2025-11-25

• Supplementary Figure S5 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

  2025-11-25

• Supplementary Figure S6 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

  2025-11-25

• Supplementary Figure S3 from Early Clearance of Plasma <i>Epidermal Growth Factor Receptor</i> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

  2025-11-25

• Variability of Circulating Tumor DNA Levels in Plasma Samples From Patients With Advanced Non–Small-Cell Lung Cancer in the Absence of Treatment

  JCO Precision Oncology · 2025-10-01 · 2 citations

• 2783P Comprehensive epigenomic profiling of plasma ctDNA enables drug target expression in SCLC

  Annals of Oncology · 2025-09-01

• Abstract P2-02-18: Agreement Across 10 Artificial Intelligence Models in Assessing HER2 in Breast Cancer Whole Slide Images: Findings from the Friends of Cancer Research Digital PATH Project

  Clinical Cancer Research · 2025-06-13 · 1 citations

• Abstract PS9-07: Epigenomic Characterization of ER Transcriptional Activation via Liquid Biopsy

  Clinical Cancer Research · 2025-06-13

• Plasma epigenomic profiling to reveal molecular correlates of response and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC).

  Journal of Clinical Oncology · 2025-05-28 · 3 citations

• Cell-free circulating chromatin profiling for epigenomic characterization of mechanisms of response and resistance to sacituzumab govitecan in breast cancer.

  Journal of Clinical Oncology · 2025-05-28 · 1 citations

• An artificial intelligence-based model for prediction of clonal hematopoiesis variants in cell-free DNA samples

  npj Precision Oncology · 2025-05-20 · 6 citations

• Abstract 668: Systematic and robust prediction of gene expression using comprehensive epigenomic profiling of plasma ctDNA

  Cancer Research · 2025-04-21

• Epigenomic profiling of circulating chromatin for early detection and monitoring of neuroendocrine prostate cancer.

  Journal of Clinical Oncology · 2025-02-10 · 1 citations

• An artificial intelligence-based model for prediction of Clonal Hematopoiesis mutants in cell-free DNA samplesPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2024-12-16 · 1 citations

• Outlining the statistical analysis of longitudinal ctDNA assays to determine minimal residual disease in patients with pancreatic ductal adenocarcinoma: the GUIDE.MRD project

  Pancreatology · 2024-12-01